Literature DB >> 9514638

Amino acid changes affecting the activity of pneumolysin alter the behaviour of pneumococci in pneumonia.

J E Alexander1, A M Berry, J C Paton, J B Rubins, P W Andrew, T J Mitchell.   

Abstract

Pneumolysin is a multi-functional toxin produced by Streptococcus pneumoniae. The toxin has distinct cytotoxic activity and complement-activating activity mediated by different parts of the toxin molecule. Mice challenged intranasally with a type 2 pneumococcal strain contract bronchopneumonia and bacteremia [1]. Mice were infected intranasally with isogenic mutants of this strain in which the chromosomal pneumolysin gene carried point mutations affecting either or both properties of pneumolysin. Reduction in either cytotoxic activity or complement activation by pneumolysin decreased the virulence of the mutant pneumococci. However, it was the ability to activate complement that most affected the behaviour of pneumococci in the lungs and associated bacteremia in the first 24 h following infection. Copyright 1998 Academic Press Limited.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9514638     DOI: 10.1006/mpat.1997.0185

Source DB:  PubMed          Journal:  Microb Pathog        ISSN: 0882-4010            Impact factor:   3.738


  20 in total

1.  Intranasal immunization of mice with a mixture of the pneumococcal proteins PsaA and PspA is highly protective against nasopharyngeal carriage of Streptococcus pneumoniae.

Authors:  D E Briles; E Ades; J C Paton; J S Sampson; G M Carlone; R C Huebner; A Virolainen; E Swiatlo; S K Hollingshead
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

2.  Induction of gamma interferon and nitric oxide by truncated pneumolysin that lacks pore-forming activity.

Authors:  Hisashi Baba; Ikuo Kawamura; Chikara Kohda; Takamasa Nomura; Yutaka Ito; Terumi Kimoto; Isao Watanabe; Satoshi Ichiyama; Masao Mitsuyama
Journal:  Infect Immun       Date:  2002-01       Impact factor: 3.441

3.  Host cellular immune response to pneumococcal lung infection in mice.

Authors:  A Kadioglu; N A Gingles; K Grattan; A Kerr; T J Mitchell; P W Andrew
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

Review 4.  Role of pore-forming toxins in bacterial infectious diseases.

Authors:  Ferdinand C O Los; Tara M Randis; Raffi V Aroian; Adam J Ratner
Journal:  Microbiol Mol Biol Rev       Date:  2013-06       Impact factor: 11.056

5.  Comparative virulence of Streptococcus pneumoniae strains with insertion-duplication, point, and deletion mutations in the pneumolysin gene.

Authors:  A M Berry; A D Ogunniyi; D C Miller; J C Paton
Journal:  Infect Immun       Date:  1999-02       Impact factor: 3.441

6.  Immunization with genetic toxoids of the Arcanobacterium pyogenes cholesterol-dependent cytolysin, pyolysin, protects mice against infection.

Authors:  B Helen Jost; Hien T Trinh; J Glenn Songer; Stephen J Billington
Journal:  Infect Immun       Date:  2003-05       Impact factor: 3.441

7.  Role of genetic resistance in invasive pneumococcal infection: identification and study of susceptibility and resistance in inbred mouse strains.

Authors:  N A Gingles; J E Alexander; A Kadioglu; P W Andrew; A Kerr; T J Mitchell; E Hopes; P Denny; S Brown; H B Jones; S Little; G C Booth; W L McPheat
Journal:  Infect Immun       Date:  2001-01       Impact factor: 3.441

8.  Lipoteichoic acid is important in innate immune responses to gram-positive bacteria.

Authors:  Ho Seong Seo; Suzanne M Michalek; Moon H Nahm
Journal:  Infect Immun       Date:  2007-10-22       Impact factor: 3.441

9.  Protection against pneumococcal pneumonia in mice by monoclonal antibodies to pneumolysin.

Authors:  María del Mar García-Suárez; María Dolores Cima-Cabal; Noelia Flórez; Pilar García; Rafael Cernuda-Cernuda; Aurora Astudillo; Fernando Vázquez; Juan R De los Toyos; F Javier Méndez
Journal:  Infect Immun       Date:  2004-08       Impact factor: 3.441

10.  Role of Toll-like receptors 2 and 4 in pulmonary inflammation and injury induced by pneumolysin in mice.

Authors:  Mark C Dessing; Robert A Hirst; Alex F de Vos; Tom van der Poll
Journal:  PLoS One       Date:  2009-11-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.